We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Life Technologies and VelaDx to Develop IVD Tests

By LabMedica International staff writers
Posted on 10 Oct 2012
VelaDx (The Kendall Science Park II, Singapore) signed an agreement with Life Technologies (Carlsbad, CA, USA) to develop and market in vitro diagnostic (IVD) tests on the Ion personal genome machine (PGM) platform. More...
VelaDx will seek approvals from global regulatory authorities for clinical diagnostic tests in oncology and infectious disease.

The Ion PGM System is fast, simple, and flexible, and is complementary to Vela's Sentosa workflow and its menu of quantitative polymerase chain reaction (qPCR) assay kits. Both Ion's PGM and Vela's Sentosa systems can operate on a menu of single tests or multiple panels that can easily be implemented in most laboratories. Data communication with laboratory information systems between the Ion PGM and Sentosa systems will maintain the accuracy of data and improve the efficiency of the laboratory workflow.

The semiconductor sequencing will increase and improve diagnostic tests for personalized medicine. Ion Torrent (Guilford, CA, USA) president and COO, Gregg Fergus explained, "The Ion PGM sequencer uses a novel sequencing technology that directly translates the language of chemistry into the binary language of computers on a semiconductor chip. This new approach has democratized sequencing, making it far more accessible than ever before. The system can perform a sequencing run in just 90 minutes and automated sample prep makes it easy for a lab technician of any experience level to operate. The cost of the Ion PGM system is just a fraction of other systems and accuracy is at a Q30 quality level, both of which are helping to rapidly drive adoption. More than 1,000 units were sold in the system's first 18 months on the market. Life Technologies plans to seek clearance for the Ion PGM System from the FDA as well as approval from other global regulatory agencies."

Target markets addressed by VelaDx are attractive and growing quickly. A recent report by Piper Jaffray, an investment bank and asset management firm, estimated the current infectious disease market to be USD 2 billion annually and growing by more than 8%. United Health Group, a health care company, predicted that the genetic testing market will grow to USD 25 billion by 2021.

Related Links:
VelaDx
Life Technologies
Ion Torrent


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.